Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Saturday, December 9, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on

December 4, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee. This award was granted pursuant to the Rigel
Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel granted stock options to purchase shares of Rigel's common stock to one employee with an exercise price of $4.09 per share, the closing price of Rigel's common stock on December 1, 2017, the first trading date prior to December 4, 2017, the effective date of such grant. The stock options vest as follows: certain of the shares of common stock subject to the award vest over a four year period, with one-fourth of the shares subject to such awards vesting on the first anniversary of the award's vesting commencement date, and the remaining shares vesting in equal monthly installments thereafter, and certain of the shares of common stock subject to the award vest immediately upon achievement of one or more performance conditions.

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. Rigel has submitted, and the FDA has accepted for review, an NDA for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Contact: Raul RodriguezPhone: 650.624.1302Email: invrel@rigel.com

 

View original content:http://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-300569160.html

SOURCE Rigel Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store